114 related articles for article (PubMed ID: 1464469)
1. In vivo enhancement of murine natural killer cell activity by 7-allyl-8-oxoguanosine (loxoribine).
Pope BL; Chourmouzis E; Sigindere J; Capetola RJ; Lau CY
Int J Immunopharmacol; 1992 Nov; 14(8):1375-82. PubMed ID: 1464469
[TBL] [Abstract][Full Text] [Related]
2. Murine strain variation in the natural killer cell and proliferative responses to the immunostimulatory compound 7-allyl-8-oxoguanosine: role of cytokines.
Pope BL; Chourmouzis E; MacIntyre JP; Lee S; Goodman MG
Cell Immunol; 1994 Dec; 159(2):194-210. PubMed ID: 7994754
[TBL] [Abstract][Full Text] [Related]
3. In vivo activation of natural killer cells and priming of IL-2 responsive cytolytic cells by loxoribine (7-allyl-8-oxoguanosine).
Pope BL; Chourmouzis E; Sigindere J; MacIntyre JP; Capetola RJ; Lau CY
Cell Immunol; 1993 Apr; 147(2):302-12. PubMed ID: 8453674
[TBL] [Abstract][Full Text] [Related]
4. Loxoribine (7-allyl-8-oxoguanosine) activates natural killer cells and primes cytolytic precursor cells for activation by IL-2.
Pope BL; Chourmouzis E; Victorino L; MacIntyre JP; Capetola RJ; Lau CY
J Immunol; 1993 Sep; 151(6):3007-17. PubMed ID: 8376766
[TBL] [Abstract][Full Text] [Related]
5. The immunostimulatory compound 7-allyl-8-oxoguanosine (loxoribine) induces a distinct subset of murine cytokines.
Pope BL; MacIntyre JP; Kimball E; Lee S; Zhou L; Taylor GR; Goodman MG
Cell Immunol; 1995 May; 162(2):333-9. PubMed ID: 7743561
[TBL] [Abstract][Full Text] [Related]
6. Immunomodulatory activity of a novel nucleoside, 7-thia-8-oxoguanosine: I. Activation of natural killer cells in mice.
Sharma BS; Mhaskar S; Balazs L; Siaw M
Immunopharmacol Immunotoxicol; 1992; 14(1-2):1-19. PubMed ID: 1597650
[TBL] [Abstract][Full Text] [Related]
7. Topology of the loxoribine binding site. Studies with inactive loxoribine analogues.
Goodman MG; Goodman JH
J Immunol; 1994 Nov; 153(9):4081-7. PubMed ID: 7930614
[TBL] [Abstract][Full Text] [Related]
8. 7-Allyl-8-oxoguanosine (loxoribine) inhibits the metastasis of B16 melanoma cells and has adjuvant activity in mice immunized with a B16 tumor vaccine.
Pope BL; Sigindere J; Chourmouzis E; MacIntyre P; Goodman MG
Cancer Immunol Immunother; 1994 Feb; 38(2):83-91. PubMed ID: 8306370
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of immunostimulatory activity by dual substitution of C8-substituted guanine ribonucleosides: correlation with increased cytokine secretion.
Pope BL; Chourmouzis E; Lee S; Goodman MG
J Immunother Emphasis Tumor Immunol; 1995 Feb; 17(2):98-108. PubMed ID: 7647961
[TBL] [Abstract][Full Text] [Related]
10. Selective modulation of elements of the immune system by low molecular weight nucleosides.
Goodman MG; Reitz AB; Chen R; Bobardt MD; Goodman JH; Pope BL
J Pharmacol Exp Ther; 1995 Sep; 274(3):1552-7. PubMed ID: 7562533
[TBL] [Abstract][Full Text] [Related]
11. Phase 1, randomized, double-blind trial of 7-allyl-8-oxoguanosine (loxoribine) in advanced cancer.
Agarwala SS; Kirkwood JM; Bryant J
Cytokines Cell Mol Ther; 2000 Dec; 6(4):171-6. PubMed ID: 11565955
[TBL] [Abstract][Full Text] [Related]
12. Small-molecule immunostimulants. Synthesis and activity of 7,8-disubstituted guanosines and structurally related compounds.
Reitz AB; Goodman MG; Pope BL; Argentieri DC; Bell SC; Burr LE; Chourmouzis E; Come J; Goodman JH; Klaubert DH
J Med Chem; 1994 Oct; 37(21):3561-78. PubMed ID: 7932584
[TBL] [Abstract][Full Text] [Related]
13. A new approach to vaccine adjuvants. Immunopotentiation by intracellular T-helper-like signals transmitted by loxoribine.
Goodman MG
Pharm Biotechnol; 1995; 6():581-609. PubMed ID: 7551237
[TBL] [Abstract][Full Text] [Related]
14. A novel guanosine analog, 7-thia-8-oxoguanosine, enhances macrophage and lymphocyte antibody-dependent cell-mediated cytotoxicity.
Jin A; Mhaskar S; Jolley WB; Robins RK; Ojo-Amaize EA
Cell Immunol; 1990 Apr; 126(2):414-9. PubMed ID: 2311125
[TBL] [Abstract][Full Text] [Related]
15. Immunotoxicity of N,N-diethylaniline in mice: effect on natural killer activity, cytotoxic T lymphocyte activity, lymphocyte proliferation response and cellular components of the spleen.
Li Q; Hirata Y; Piao S; Minami M
Toxicology; 2000 Sep; 150(1-3):179-89. PubMed ID: 10996674
[TBL] [Abstract][Full Text] [Related]
16. New perspectives on the approach to chronic lymphocytic leukemia.
Goodman MG; Spinosa JC; Saven A; Piro LD; Wormsley S
Leuk Lymphoma; 1996 Jun; 22(1-2):1-10. PubMed ID: 8724523
[TBL] [Abstract][Full Text] [Related]
17. Augmentation of mouse liver-associated natural killer activity by biologic response modifiers occurs largely via rapid recruitment of large granular lymphocytes from the bone marrow.
Wiltrout RH; Pilaro AM; Gruys ME; Talmadge JE; Longo DL; Ortaldo JR; Reynolds CW
J Immunol; 1989 Jul; 143(1):372-8. PubMed ID: 2732472
[TBL] [Abstract][Full Text] [Related]
18. Augmentation of mouse natural killer cell activity by LS 2616, a new immunomodulator.
Kalland T; Alm G; Stålhandshe T
J Immunol; 1985 Jun; 134(6):3956-61. PubMed ID: 2580900
[TBL] [Abstract][Full Text] [Related]
19. In vivo boosting of lung natural killer and lymphokine-activated killer cell activity by interleukin-2: comparison of systemic, intrapleural and inhalation routes.
Flexman JP; Manning LS; Robinson BW
Clin Exp Immunol; 1990 Oct; 82(1):151-6. PubMed ID: 2208789
[TBL] [Abstract][Full Text] [Related]
20. Roles of interferon and natural killer cells in the antiviral activity of 7-thia-8-oxoguanosine against Semliki Forest virus infections in mice.
Smee DF; Alaghamandan HA; Jin A; Sharma BS; Jolley WB
Antiviral Res; 1990 Feb; 13(2):91-102. PubMed ID: 1693058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
